| Revenue growth | 10.6% YoY in Q3; 9.4% YoY in 9M FY26. |
|---|---|
| Margins | Gross margin expanded 184bps to 58.1% due to soft raw material costs. |
| Order book | U.S. order book at $220 million plus. |
| Demand visibility | Strong U.S. order book; seasonal uptick in cough/cold/pain segments. |
| Management confidence | High; optimistic on U.S. market and European expansion. |
Growth
Revenue grew 10.6% YoY to ₹754.4cr; EBITDA up 23.2% to ₹160.7cr; PAT up 8.2% to ₹113.7cr.
Outlook
Targeting ₹4,000cr revenue milestone by FY28/29; aggressive U.K. filings; active acquisition search in Europe.
Risks
Rx price erosion in U.K./U.S.; geopolitical uncertainties; macroeconomic challenges in Rest of World markets.
Earnings Call filed with NSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹324.40
- Market cap
- ₹14,701 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 28.4×Sector 47.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY